TNF-α is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression

Clinical Immunology

Volumn 146, Issue 1, 2013, Pages 15-25

  Iwamoto, Satoru ^a   Kido, Masahiro ^a   Aoki, Nobuhiro ^a   Nishiura, Hisayo ^a   Maruoka, Ryutaro ^a   Ikeda, Aki ^a   Okazaki, Taku ^b   Chiba, Tsutomu ^a   Watanabe, Norihiko ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Autoimmune hepatitis; ; CCL20; ; Mouse model; ; TNF antagonist; TNF ;

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHEMOKINE RECEPTOR CCR6; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL STIMULATION; CONTROLLED STUDY; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FATALITY; IN VIVO STUDY; LIVER CELL; LYMPHOCYTE MIGRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYMECTOMY; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CCL20; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HEPATITIS, AUTOIMMUNE; HEPATOCYTES; KAPLAN-MEIER ESTIMATE; LIVER; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PROGRAMMED CELL DEATH 1 RECEPTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; SURVIVAL RATE; T-LYMPHOCYTES; THYMECTOMY; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84869869355     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.10.008     Document Type: Article

References (33)

1. Ware C.F. Network communications: lymphotoxins, LIGHT, and TNF. Annu. Rev. Immunol. 2005, 23:787-819.
2. Wong M., Ziring D., Korin Y., Desai S., Kim S., Lin J., Gjertson D., Braun J., Reed E., Singh R.R. TNF alpha blockade in human diseases: mechanisms and future directions. Clin. Immunol. 2008, 126:121-136.
3. Lin J., Ziring D., Desai S., Kim S., Wong M., Korin Y., Braun J., Reed E., Gjertson D., Singh R.R. TNF alpha blockade in human diseases: an overview of efficacy and safety. Clin. Immunol. 2008, 126:13-30.
4. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 2008, 117:244-279.
5. Schwabe R.F., Brenner D.A. Mechanisms of liver injury. I. TNF-α-induced liver injury: role of IKK, JNK, and ROS pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G583-G589.
6. Maggiore G., De Benedetti F., Massa M., Pignatti P., Martini A. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. J. Pediatr. Gastroenterol. Nutr. 1995, 20:23-27.
7. Czaja A.J., Cookson S., Constantini P.K., Clare M., Underhill J.A., Donaldson P.T. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmunehepatitis. Gastroenterology 1999, 117:645-652.
8. Cookson S., Constantini P.K., Clare M., Underhill J.A., Bernal W., Czaja A.J., Donaldson P.T. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999, 30:851-856.
9. Gorham J.D., Lin J.T., Sung J.L., Rudner L.A., French M.A. Genetic regulation of autoimmune disease: BALB/c background TGF-beta 1-deficient mice develop necroinflammatory IFN-gamma-dependent hepatitis. J. Immunol. 2001, 166:6413-6422.
10. Robinson R.T., Wang J., Cripps J.G., Milks M.W., English K.A., Pearson T.A., Gorham J.D. End-organ damage in a mouse model of fulminant liver inflammation requires CD4+ T cell production of IFN-γ but is independent of Fas. J. Immunol. 2009, 182:3278-3284.
11. Oya Y., Watanabe N., Owada T., Oki M., Hirose K., Suto A., Kagami S., Nakajima H., Kishimoto T., Iwamoto I., Murphy T.L., Murphy K.M., Saito Y. Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum. 2008, 58:2498-2510.
12. Holdener M., Hintermann E., Bayer M., Rhode A., Rodrigo E., Hintereder G., Johnson E.F., Gonzalez F.J., Pfeilschifter J., Manns M.P., Herrath M.G., Christen U. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J. Exp. Med. 2008, 205:1409-1422.
13. Tamaki S., Homma S., Enomoto Y., Komita H., Zeniya M., Ohno T., Toda G. Autoimmune hepatic inflammation by vaccination of mice with dendritic cells loaded with well-differentiated hepatocellular carcinoma cells and administration of interleukin-12. Clin. Immunol. 2005, 117:280-293.
14. Zierden M., Kühnen E., Odenthal M., Dienes H.P. Effects and regulation of autoreactive CD8+ T cells in a transgenic mouse model of autoimmune hepatitis. Gastroenterology 2010, 139:975-986.
15. Tiegs G., Hentschel J., Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J. Clin. Invest. 1992, 90:196-203.
16. Mizuhara H., O'Neill E., Seki N., Ogawa T., Kusunoki C., Otsuka K., Satoh S., Niwa M., Senoh H., Fujiwara H. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J. Exp. Med. 1994, 179:1529-1537.
17. Tagawa Y., Sekikawa K., Iwakura Y. Suppression of concanavalin A-induced hepatitis in IFN-γ(-/-) mice, but not in TNF-α(-/-) mice: role for IFN-γ in activating apoptosis of hepatocytes. J. Immunol. 1997, 159:1418-1428.
18. Kido M., Watanabe N., Okazaki T., Akamatsu T., Tanaka J., Saga K., Nishio A., Honjo T., Chiba T. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology 2008, 135:1333-1343.
19. Aoki N., Kido M., Iwamoto S., Nishiura H., Maruoka R., Tanaka J., Watanabe T., Tanaka Y., Okazaki T., Chiba T., Watanabe N. Dysregulated generation of follicular helper T cells in the spleen triggers fatal autoimmune hepatitis in mice. Gastroenterology 2011, 140:1322-1333.
20. Nishimura H., Okazaki T., Tanaka Y., Nakatani K., Hara M., Matsumori A., Sasayama S., Mizoguchi A., Hiai H., Minato N., Honjo T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001, 291:319-322.
21. Seglen P.O. Preparation of isolated rat liver cells. Methods Cell Biol. 1976, 13:29-83.
22. Fujiwara M., Marusawa H., Wang H.Q., Iwai A., Ikeuchi K., Imai Y., Kataoka A., Nukina N., Takahashi R., Chiba T. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene 2008, 27:6002-6011.
23. Rossi D.L., Vicari A.P., Franz-Bacon K., McClanahan T.K., Zlotnik A. Identification through bioinformatics of two new macrophage proinflammatory human chemokines: MIP-3α and MIP-3β. J. Immunol. 1997, 158:1033-1036.
24. Reboldi A., Coisne C., Baumjohann D., Benvenuto F., Bottinelli D., Lira S., Uccelli A., Lanzavecchia A., Engelhardt B., Sallusto F. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 2009, 10:514-523.
25. Sugita S., Kohno T., Yamamoto K., Imaizumi Y., Nakajima H., Ishimaru T., Matsuyama T. Induction of macrophage-inflammatory protein-3alpha gene expression by TNF-dependent NF-kappaB activation. J. Immunol. 2002, 168:5621-5628.
26. Shimizu Y., Murata H., Kashii Y., Hirano K., Kunitani H., Higuchi K., Watanabe A. CC-chemokine receptor 6 and its ligand macrophage inflammatory protein 3alpha might be involved in the amplification of local necroinflammatory response in the liver. Hepatology 2001, 34:311-319.
27. Roth E., Pircher H. IFN-γ promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells. J. Immunol. 2004, 172:1588-1594.
28. Rowe I.A., Webb K., Gunson B.K., Mehta N., Hague S., Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl. Int. 2008, 21:459-465.
29. Schramm C., Bubenheim M., Adam R., Karam V., Buckels J., O'Grady J.G., Jamieson N., Pollard S., Neuhaus P., Manns M.M., Porte R., Castaing D., Paul A., Traynor O., Garden J., Friman S., Ericzon B.G., Fischer L., Vitko S., Krawczyk M., Metselaar H.J., Foss A., Kilic M., Rolles K., Burra P., Rogiers X., Lohse A.W. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl. 2010, 16:461-469.
30. Weiler-Normann C., Wiegard C., Schramm C., Lohse A.W. A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade. Am. J. Gastroenterol. 2009, 104:2877-2878.
31. Ramos-Casals M., Roberto-Perez-Alvarez, Diaz-Lagares C., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun. Rev. 2010, 9:188-193. BIOGEAS Study Group.
32. Cravo M., Silva R., Serrano M. Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab. BioDrugs 2010, 24(Suppl. 1):25-27.
33. Del Prete C.J., Cohen N.S. A case of Rituximab-induced hepatitis. Cancer Biother. Radiopharm. 2010, 25:747-748.